Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2023-03-17 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
关于子公司收到药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from a company about its subsidiary receiving a drug registration certificate from the national drug regulatory authority. It contains no financial data, no detailed financial performance, no management discussion, no voting results, no legal proceedings, and no mention of any report publication. The document is an official announcement about a regulatory approval event related to the company's product line. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or others that require financial or management content. Given the nature of the announcement and its brevity, it best fits into the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2023-03-17 Chinese
关于子公司收到药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (702 characters) about a subsidiary receiving a drug registration certificate from a national regulatory authority. It contains no financial data, no detailed report, and no mention of financial results or management changes. It is an official announcement of a regulatory event related to product registration, not a financial report or management disclosure. Given its brevity and content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-03-13 Chinese
关于子公司收到药品补充申请批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (731 characters) from a company about its subsidiary receiving an approval notice from the National Medical Products Administration regarding a drug supplement application. It does not contain financial statements, detailed financial data, or comprehensive report content. It is an official announcement about regulatory approval related to a product, not a financial report or management discussion. The document is not a report itself but an announcement of a regulatory event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-03-13 Chinese
关于子公司收到药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (716 characters) regarding a subsidiary receiving a drug registration certificate from the national drug regulatory authority. It contains no financial data, no detailed report, and no mention of financial results or management discussion. It is an official company announcement about a regulatory approval event. The document is not a full report, earnings release, or management report. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other specific categories.
2023-03-06 Chinese
关于子公司收到药品补充申请批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company about its subsidiary receiving an approval notice from the National Medical Products Administration for a drug supplement application. It contains no financial data, no management or board changes, no voting results, no earnings or annual report content. It is a regulatory announcement about product approval, which fits best under Regulatory Filings (RNS) as it does not fit other specific categories.
2023-02-28 Chinese
关于子公司收到药品补充申请批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding its subsidiary receiving an approval notice from the National Medical Products Administration for a drug supplement application. It contains no financial data, no report or presentation, and is not related to shareholder meetings, management changes, or legal proceedings. It is a regulatory announcement about product approval and potential impact on business, which fits best under Regulatory Filings (RNS). The document length is short and it is an announcement, not a full report.
2023-02-24 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.